Company / Return on Equity (ROE)
Amgen Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
89.1%
FY2025
5-year range
69.6% / 107.8%
FY2021-FY2025
Trend
+28.0%
vs FY2024
Sector context
#3 of 190
Health Care
What the data says
Among 190 Health Care companies, Amgen is in the top 2% for return on equity (roe). Return on Equity (ROE) has fluctuated over the past 10 years, ranging from 7.8% in FY2019 to 107.8% in FY2023.
Based on SEC 10-K filings.
89.1% in FY2025 with a 5-year CAGR of +21.9%. Ranks 3rd among 190 companies in Health Care.
Declined from 107.8% to 89.1% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +11.9pp
- 5-Year Change
- +21.9pp
- 10-Year Change
- -
Sector benchmark
Top 2% in Health CareTop 2% of 190This company 89.1% Sector average -50.3%
▼
+277.0% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 28.0% year-over-year.
- Currently 139.4pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2023.
- Lowest return on equity (roe) in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 89.1% | +28.0% |
| FY2024 | 69.6% | -35.4% |
| FY2023 | 107.8% | +39.6% |
| FY2022 | 77.2% | -4.8% |
| FY2021 | 81.1% | +20.7% |
| FY2020 | 67.2% | +756.5% |
| FY2019 | 7.8% | -69.7% |
| FY2018 | 25.9% | +4.6% |
| FY2017 | 24.7% | +23.5% |
| FY2016 | 20.0% | -19.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026